Regulus Therapeutics’ (RGLS) “Buy” Rating Reaffirmed at HC Wainwright

Regulus Therapeutics (NASDAQ:RGLS)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a research note issued on Friday,Benzinga reports. They currently have a $10.00 target price on the biopharmaceutical company’s stock.

Regulus Therapeutics Stock Down 6.8 %

Shares of NASDAQ RGLS opened at $1.38 on Friday. The firm has a 50-day simple moving average of $1.28 and a 200-day simple moving average of $1.46. The stock has a market capitalization of $90.39 million, a price-to-earnings ratio of -1.29 and a beta of 1.41. Regulus Therapeutics has a 52 week low of $0.83 and a 52 week high of $3.00.

Regulus Therapeutics (NASDAQ:RGLS) last issued its earnings results on Thursday, March 20th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, hitting the consensus estimate of ($0.20). During the same period last year, the firm earned ($0.40) EPS. As a group, equities research analysts expect that Regulus Therapeutics will post -0.88 EPS for the current year.

Insiders Place Their Bets

In related news, VP Christopher Ray Aker sold 38,547 shares of the stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $1.26, for a total value of $48,569.22. Following the completion of the transaction, the vice president now directly owns 54,634 shares in the company, valued at approximately $68,838.84. This represents a 41.37 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Preston Klassen sold 31,445 shares of Regulus Therapeutics stock in a transaction on Monday, January 13th. The shares were sold at an average price of $1.26, for a total value of $39,620.70. Following the completion of the sale, the insider now owns 36,055 shares in the company, valued at $45,429.30. This represents a 46.59 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 223,998 shares of company stock valued at $282,237 in the last three months. 4.35% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of RGLS. Jane Street Group LLC purchased a new stake in shares of Regulus Therapeutics in the 3rd quarter valued at approximately $46,000. PEAK6 LLC purchased a new stake in Regulus Therapeutics in the fourth quarter valued at approximately $95,000. Velan Capital Investment Management LP acquired a new stake in shares of Regulus Therapeutics in the fourth quarter valued at $111,000. JPMorgan Chase & Co. raised its holdings in shares of Regulus Therapeutics by 193.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 78,972 shares of the biopharmaceutical company’s stock valued at $124,000 after buying an additional 52,059 shares during the period. Finally, Barclays PLC lifted its stake in Regulus Therapeutics by 285.2% during the 3rd quarter. Barclays PLC now owns 84,477 shares of the biopharmaceutical company’s stock worth $132,000 after acquiring an additional 62,549 shares in the last quarter. Hedge funds and other institutional investors own 92.38% of the company’s stock.

About Regulus Therapeutics

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.